Blisibimod Misses PEARL-SC Endpoint; Anthera Plummets
Shares of Anthera Pharmaceuticals Inc. struggled to find a floor Thursday after the company reported following the market's close Wednesday afternoon that its Phase IIb PEARL-SC study of blisibimod in systemic lupus erythematosus (SLE) failed to meet the primary efficacy endpoint – clinical improvement at 24 weeks in the SLE responder index for the pooled blisibimod dose groups – due to lack of efficacy in two low-dose groups.
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter